Cargando…
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177687/ https://www.ncbi.nlm.nih.gov/pubmed/32244396 http://dx.doi.org/10.3390/ijms21072411 |
_version_ | 1783525274163347456 |
---|---|
author | Hernandez, Carlos Arasanz, Hugo Chocarro, Luisa Bocanegra, Ana Zuazo, Miren Fernandez-Hinojal, Gonzalo Blanco, Ester Vera, Ruth Escors, David Kochan, Grazyna |
author_facet | Hernandez, Carlos Arasanz, Hugo Chocarro, Luisa Bocanegra, Ana Zuazo, Miren Fernandez-Hinojal, Gonzalo Blanco, Ester Vera, Ruth Escors, David Kochan, Grazyna |
author_sort | Hernandez, Carlos |
collection | PubMed |
description | The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of the patients benefit from ICI therapies. Many efforts have been made for the identification of biomarkers allowing patient stratification into potential responders and progressors before the start of ICI therapies or for monitoring responses during treatment. While much attention is centered on biomarkers from the tumor microenvironment, in many cases biopsies are not available. The identification of systemic immune cell subsets that correlate with responses could provide promising biomarkers. Some of them have been reported to influence the response to ICI therapies, such as proliferation and activation status of CD8 and CD4 T cells, the expression of immune checkpoints in peripheral blood cells and the relative numbers of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. In addition, the profile of soluble factors in plasma samples could be associated to response or tumor progression. Here we will review the cellular subsets associated to response or progression in different studies and discuss their accuracy in diagnosis. |
format | Online Article Text |
id | pubmed-7177687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71776872020-04-28 Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies Hernandez, Carlos Arasanz, Hugo Chocarro, Luisa Bocanegra, Ana Zuazo, Miren Fernandez-Hinojal, Gonzalo Blanco, Ester Vera, Ruth Escors, David Kochan, Grazyna Int J Mol Sci Review The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of the patients benefit from ICI therapies. Many efforts have been made for the identification of biomarkers allowing patient stratification into potential responders and progressors before the start of ICI therapies or for monitoring responses during treatment. While much attention is centered on biomarkers from the tumor microenvironment, in many cases biopsies are not available. The identification of systemic immune cell subsets that correlate with responses could provide promising biomarkers. Some of them have been reported to influence the response to ICI therapies, such as proliferation and activation status of CD8 and CD4 T cells, the expression of immune checkpoints in peripheral blood cells and the relative numbers of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. In addition, the profile of soluble factors in plasma samples could be associated to response or tumor progression. Here we will review the cellular subsets associated to response or progression in different studies and discuss their accuracy in diagnosis. MDPI 2020-03-31 /pmc/articles/PMC7177687/ /pubmed/32244396 http://dx.doi.org/10.3390/ijms21072411 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hernandez, Carlos Arasanz, Hugo Chocarro, Luisa Bocanegra, Ana Zuazo, Miren Fernandez-Hinojal, Gonzalo Blanco, Ester Vera, Ruth Escors, David Kochan, Grazyna Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies |
title | Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies |
title_full | Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies |
title_fullStr | Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies |
title_full_unstemmed | Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies |
title_short | Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies |
title_sort | systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177687/ https://www.ncbi.nlm.nih.gov/pubmed/32244396 http://dx.doi.org/10.3390/ijms21072411 |
work_keys_str_mv | AT hernandezcarlos systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies AT arasanzhugo systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies AT chocarroluisa systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies AT bocanegraana systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies AT zuazomiren systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies AT fernandezhinojalgonzalo systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies AT blancoester systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies AT veraruth systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies AT escorsdavid systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies AT kochangrazyna systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies |